Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Minimal CBX3-Derived UCOE Confers Long-Term Resistance to Transgene Silencing in Human iPSCs During Neuronal Differentiation

Long-term transgene silencing remains a major challenge in lentiviral gene delivery, particularly in pluripotent stem cells undergoing lineage-specific differentiation. Universal chromatin opening elements (UCOEs) have emerged as effective regulatory elements for protecting transgene expression against epigenetic silencing; however, their relatively large-size limits vector design flexibility. In the present study, we evaluated the anti-silencing activity of three next-generation UCOE constructs (1.7 kb, 1.2 kb, and a newly developed minimal 0.5 kb fragment) during long-term culture and neuronal differentiation of human induced pluripotent stem cells (iPSCs). UCOE fragments were cloned into self-inactivating lentiviral vectors and validated by restriction enzyme analysis and agarose gel electrophoresis. Lentiviral particles produced in HEK293T cells were used to transduce human iPSCs, followed by neuronal differentiation. Transgene expression was monitored for up to 60 days using fluorescence microscopy, confocal immunofluorescence, flow cytometry, and vector copy number analysis by quantitative PCR. All UCOE-containing vectors demonstrated significantly improved transgene stability compared with the UCOE-less control throughout both the undifferentiated and differentiated stages. The UCOE-containing constructs maintained substantially greater expression stability than the UCOE-less control, with the minimal 0.5 kb UCOE showing long-term performance comparable to the larger UCOE constructs. These findings demonstrate that considerable UCOE minimization can be achieved without markedly compromising anti-silencing activity, providing a potential vector-design advantage by reducing the regulatory cassette footprint and increasing available vector capacity. The compact 0.5 kb UCOE therefore represents a promising regulatory element for sustained transgene expression in stem cell engineering, disease modeling, regenerative medicine, and future gene therapy applications. However, the present study did not directly assess genomic safety, insertional effects, genotoxicity, or cellular transformation, and dedicated preclinical studies will be required to determine the long-term safety and in vivo performance of this compact UCOE configuration.

O. Anakok, G. Akcay · 0 citations
Review Open access Sep 2026

Experimental epilepsy models for mechanistic investigation and translational research

Epilepsy is not merely a chronic neurological disorder characterized by recurrent, spontaneous seizures at the clinical level; rather, it represents a complex pathophysiological condition involving profound structural, functional, and molecular reorganization within neuronal networks. The marked heterogeneity of epilepsy arises from the multilayered interplay of genetic susceptibility, acquired brain insults such as trauma, ischemia, or infection, developmental abnormalities, and environmental factors. This multifactorial etiology poses substantial challenges for clinical management and limits the effectiveness of current therapeutic approaches, which are largely restricted to symptomatic seizure suppression. Experimental epilepsy models constitute indispensable tools for addressing these unmet clinical and scientific needs. Chemical, electrical, genetic, and acquired models enable systematic investigation of epilepsy across multiple biological scales, ranging from alterations in neuronal excitability and synaptic plasticity to neuroinflammatory processes and network-level synchronization disturbances. Beyond providing mechanistic insight, these models serve as essential platforms for preclinical evaluation of novel pharmacological agents and neuromodulation-based therapeutic strategies. The review encompasses a broad experimental spectrum, including chemoconvulsant models such as pentylenetetrazol, pilocarpine, and kainic acid; electrical stimulation paradigms; genetic and developmental models; and acquired epilepsy models. In addition, in vitro and ex vivo systems, outcome measures, and model optimization strategies for drug screening and therapeutic development are discussed. By highlighting the limitations of single-model approaches and emphasizing complementary experimental strategies, this review aims to advance a comprehensive understanding of epilepsy pathophysiology and support the development of more effective, mechanism-based therapies.

Ali Osman Arslan, Sevdenur Akcay, G. Akcay · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.